

Supplementary

Table S1 Information of primary antibodies used in this study

Antibody	Vendor	Catalog No.
BST-2	Proteintech	13560-1-AP
p65	Proteintech	10745-1-AP
IκB α	Cell Signaling Technology	9242S
p-IκB α	Cell Signaling Technology	9246S
AKT	BBI Life Science	D160001
p-AKT	BBI Life Science	D155156
ERK1/2	BBI Life Science	D160317
p-ERK1/2	BBI Life Science	D151580
β -tubulin	Beijing Ray Antibody Biotech	RM2003
HA tag	Invitrogen	71-5500
Myc tag	Millipore	05-724

Table S2 Oligonucleotides used for qRT-PCR

Gene	Oligonucleotides (5'→3')
<i>BST-2</i>	F: ACGCGTCTGCAGAGGTG R: GGCCCAGCAGCACAAAT
<i>GAPDH</i>	F: TGCACCACCAACTGCTTAGC R: GGCATGGACTGTGGTCATGAG
<i>EDEM1</i>	F: TCCTTAAAGGGGAAGCGAGCC R: AGCGCTGCCATTGCATGGT
<i>EDEM2</i>	F: AGTGGTTGAAGTGCTCCAGGA R: CAGCCTCTACTTCCACCCCA
<i>EDEM3</i>	F: GGCTTGGTGGCTTCGGGAAA R: ACATTGCTGGACGCTGGTGG
<i>Bcl-xL</i>	F: CGTGGAAAGCGTAGACAAGGA R: AGAGTGAGCCCAGCAGAACCC
<i>CIAP2</i>	F: CTTTGCTGTGATGGTGGACTC R: TCTCCTGGGCTGTCTGATGTG
<i>FLIP</i>	F: ACCCTCACCTGTTCCGGACT R: TGCCCTGGCCCATGTAAT
<i>Livin</i>	F: GTCAGTTCTGCTCCGGTCA R: GCTGCGTCTCCGGTTCTT
β -Actin	F: ACCGAGCGCGGCTACAG R: CTTAATGTCACGCACGATTCC
<i>HMBS</i>	F: GGCAATGCGGCTGCAA R: GGGTACCCACGCGAATCAC




Figure S1 N-glycosylation of BST-2 involves HCC tumorigenesis in L02 cells. (A) Cell proliferation of L02:WT, L02:N65/92A, and control cells was measured by CCK8. (B) Cell migration of L02:WT, L02:N65/92A, and control cells was measured and quantified by wound healing assays. (C) Colony formation of L02:WT, L02:N65/92A, and control cells was measured and quantified. The results are reported as the mean \pm SD of three independent experiments. ns, no significance; *, P<0.05; **, P<0.01.